Randomized, double‐blind, placebo‐controlled trial of the once‐daily <scp>GLP</scp>‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (<scp>GetGoal</scp>‐L‐Asia)
Diabetes, obesity & metabolism/Diabetes, obesity and metabolism